SignatureFD’s Ocular Therapeutix OCUL Stock Holding History

SignatureFD’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-341	Closed	-$2.89K	–	3595
2026 Q1	$2.89K	Buy	+341	New	+$3.25K	﹤0.01%	2951
2025 Q2	–	Sell	-781	Closed	-$5.72K	–	3377
2025 Q1	$5.72K	Buy	+781	New	+$6K	﹤0.01%	2552
2024 Q2	–	Sell	-76	Closed	-$692	–	3216
2024 Q1	$692	Buy	+76	New	+$539	﹤0.01%	2990
2023 Q2	–	Sell	-192	Closed	-$1.01K	–	3326
2023 Q1	$1.01K	Buy	+192	New	+$912	﹤0.01%	2991
2022 Q4	–	Sell	-1,195	Closed	-$5K	–	3376
2022 Q3	$5K	Buy	+1,195	New	+$6.02K	﹤0.01%	2447
2021 Q4	–	Sell	-134	Closed	-$1K	–	3218
2021 Q3	$1K	Hold	134	–	–	﹤0.01%	2875
2021 Q2	$2K	Hold	134	–	–	﹤0.01%	2605
2021 Q1	$2K	Hold	134	–	–	﹤0.01%	2508
2020 Q4	$3K	Hold	134	–	–	﹤0.01%	2159
2020 Q3	$1K	Buy	+134	New	+$1.11K	﹤0.01%	2467

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SignatureFD's OCUL Position: Q2 2026 in Review

SignatureFD sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 341 shares — an estimated $2.89K sold.

SignatureFD first reported a position in OCUL in Q3 2020 and held it in 10 quarters. The position peaked at $5.72K in Q1 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

SignatureFD reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
SignatureFD sold 341 Ocular Therapeutix shares in Q2 2026, an estimated $2.89K.
SignatureFD first reported a position in Ocular Therapeutix in Q3 2020 and held it in 10 quarters.
SignatureFD's Ocular Therapeutix position peaked at $5.72K in Q1 2025.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.